FDA to review Puma Biotech's neratinib for the treatment of HER2-positive early stage breast cancer

|About: Puma Biotechnology, Inc. (PBYI)|By:, SA News Editor

The FDA's Oncologic Drugs Advisory Committee  will meet on May 24 to review and discuss Puma Biotechnology's (NYSE:PBYI) New Drug Application (NDA) seeking approval of neratinib for the treatment of HER2-positive breast cancer.

Neratinib is an investigational therapy for the extended adjuvant treatment of early stage HER2-positive breast cancer that has previously been treated with a trastuzumab containing regimen.